LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $10.00

LifeStance Health Group (NASDAQ:LFST) had its price target lifted by Canaccord Genuity Group from $9.00 to $10.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently issued reports on LFST. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. BTIG Research raised their price target on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Finally, Barclays started coverage on LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.67.

LifeStance Health Group Price Performance

LFST opened at $7.24 on Thursday. The company has a market capitalization of $2.82 billion, a P/E ratio of 362.18 and a beta of 1.12. The company has a 50-day moving average of $7.13 and a 200-day moving average of $6.21. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. LifeStance Health Group has a 1-year low of $3.74 and a 1-year high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.02). LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.66%. The firm had revenue of $382.20 million for the quarter, compared to analyst estimates of $378.51 million. During the same period in the prior year, the company posted ($0.01) earnings per share. The business’s revenue was up 17.4% on a year-over-year basis. Equities analysts expect that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

LifeStance Health Group declared that its Board of Directors has authorized a share buyback program on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 3.6% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s management believes its stock is undervalued.

Insider Activity at LifeStance Health Group

In related news, insider Ann Varanakis sold 50,000 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the sale, the insider directly owned 315,610 shares of the company’s stock, valued at approximately $2,177,709. This represents a 13.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Bessler sold 119,942 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the transaction, the director owned 1,318,983 shares in the company, valued at $9,285,640.32. This trade represents a 8.34% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 270,086 shares of company stock valued at $1,891,264. 3.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of LifeStance Health Group by 63.4% during the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after buying an additional 27,244 shares during the last quarter. AQR Capital Management LLC increased its position in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after acquiring an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in LifeStance Health Group by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after purchasing an additional 4,169 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in LifeStance Health Group by 1.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after purchasing an additional 11,331 shares during the last quarter. Finally, Corton Capital Inc. boosted its holdings in LifeStance Health Group by 97.7% in the 2nd quarter. Corton Capital Inc. now owns 26,655 shares of the company’s stock valued at $138,000 after purchasing an additional 13,171 shares during the period. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.